Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

featured

Published in Metastatic Breast Cancer and

Expert Opinion / Interview · July 14, 2016

Implications for Treatment of Estrogen Receptor Mutations

Interview by

Farzanna S Haffizulla MD, FACP, FAMWA

Interview with

Kimberly L Blackwell MD

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Sign in

Not a member?

Join for free

Additional Info

Disclosures

Disclosure statements are available on the authors' profiles:

Kimberly Blackwell MD

featured

Efficacy and Safety of Trastuzumab Duocarmazine in Pretreated Patients With HER2+ Advanced or Metastatic Breast Cancer

J. Clin. Oncol · November 12, 2024
story of the week

Real-World Effectiveness of Palbociclib Plus Endocrine Therapy in HR+/HER2− Advanced Breast Cancer

Oncologist · November 11, 2024
featured

Efficacy of Neratinib Plus Ado-Trastuzumab Emtansine for Pretreated and Untreated HER2+ Breast Cancer Brain Metastases

Ann. Oncol · November 07, 2024
story of the week

Real-World Effectiveness of Palbociclib Plus Aromatase Inhibitors in Patients With Metastatic Breast Cancer and Cardiovascular Diseases

Oncologist · November 04, 2024
featured

Efficacy and Safety of Trastuzumab Deruxtecan Plus Nivolumab in Patients With HER2-Expressing Metastatic Breast or Urothelial Cancer

Clin. Cancer Res · October 30, 2024
story of the week

Predictors of Response to CDK4/6i Retrial After Prior CDK4/6i Treatment Failure in ER+ Metastatic Breast Cancer

NPJ Breast Cancer · October 28, 2024
featured

Prophylactic Efficacy of Olanzapine-Based Therapy for Trastuzumab Deruxtecan–Associated Nausea and Vomiting in Patients With HER2-Positive or HER2-Low Breast Cancer

Ann. Oncol · October 24, 2024

updated
featured

Outcomes and Prognostic Factors Associated With Brain Metastasis in Triple-Negative Breast Cancer

Breast J · October 22, 2024
story of the week

Outcomes of Datopotamab Deruxtecan vs Chemotherapy in Previously Treated Patients With Inoperable/Metastatic HR+/HER2− Breast Cancer

J. Clin. Oncol · October 21, 2024
featured

Pharmacokinetics and Pharmacogenomics of Ribociclib in Black Patients With Metastatic Breast Cancer

NPJ Breast Cancer · October 15, 2024
story of the week

Efficacy and Safety of Elacestrant in ER+/HER2− MBC With ESR1-Mutated Tumors Based on Prior Duration of Endocrine Therapy Plus CDK4/6i and in Clinical Subgroups

Clin. Cancer Res · October 14, 2024

Metastatic Breast Cancer

Implications for Treatment of Estrogen Receptor Mutations

Additional Info

Further Reading

Efficacy and Safety of Trastuzumab Duocarmazine in Pretreated Patients With HER2+ Advanced or Metastatic Breast Cancer

Real-World Effectiveness of Palbociclib Plus Endocrine Therapy in HR+/HER2− Advanced Breast Cancer

Efficacy of Neratinib Plus Ado-Trastuzumab Emtansine for Pretreated and Untreated HER2+ Breast Cancer Brain Metastases

Real-World Effectiveness of Palbociclib Plus Aromatase Inhibitors in Patients With Metastatic Breast Cancer and Cardiovascular Diseases

Efficacy and Safety of Trastuzumab Deruxtecan Plus Nivolumab in Patients With HER2-Expressing Metastatic Breast or Urothelial Cancer

Predictors of Response to CDK4/6i Retrial After Prior CDK4/6i Treatment Failure in ER+ Metastatic Breast Cancer

Prophylactic Efficacy of Olanzapine-Based Therapy for Trastuzumab Deruxtecan–Associated Nausea and Vomiting in Patients With HER2-Positive or HER2-Low Breast Cancer

Outcomes and Prognostic Factors Associated With Brain Metastasis in Triple-Negative Breast Cancer

Outcomes of Datopotamab Deruxtecan vs Chemotherapy in Previously Treated Patients With Inoperable/Metastatic HR+/HER2− Breast Cancer

Pharmacokinetics and Pharmacogenomics of Ribociclib in Black Patients With Metastatic Breast Cancer

Efficacy and Safety of Elacestrant in ER+/HER2− MBC With ESR1-Mutated Tumors Based on Prior Duration of Endocrine Therapy Plus CDK4/6i and in Clinical Subgroups

Related Videos